- Naturally derived oil and inhalable cannabigerol ("CBG")
products added to MediPharm's wellness portfolio – the benefits of
CBG without the effects of THC.
- New CBG products include Advanced Formula, which is a CBG:CBD
1:2 oil, and Northbound, which is a high CBG vape cartridge with
CBD inspired by The White and Appalachia strains.
- Launches first ever MediPharm-produced water-soluble product
based on a proprietary CBN formulation. MediPharm continues to lead
the industry in CBN products.
BARRIE, ON, April 5, 2022 /PRNewswire/ - MediPharm
Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm
Labs", "MediPharm" or the "Company") a pharmaceutical company
specialized in precision-based cannabinoids, is pleased to announce
the expansion of its adult use wellness product line with the
launch of CBG and water-soluble products. As of today, these new
products will be available in Ontario in both retail stores and on the
OCS.ca e-commerce website. MediPharm also has purchase commitments
to distribute the products to the Company's other seven provincial
distributors in the coming months.
Bryan Howcroft CEO of MediPharm commented, "Over the
past 16 months, MediPharm has formulated several innovative product
platforms, launched them and gained traction in the premium
wellness segment of the Canadian market. The announcement today
expands the Company's portfolio to include the first naturally
derived CBG products available to Canadian adult consumers and the
only inhalable CBG option in Canada. With recent investments in sales and
marketing functions demonstrating tangible results, our team will
continue to bring differentiated wellness-focused products to
market, and work to grow shelf presence as the year progresses. We
also see a meaningful opportunity to introduce products such as
those launched today into international markets, leveraging our
unique GMP Drug Establishment and Natural Health Product
manufacturing licenses, and existing global distribution
partnerships."
MediPharm Labs CBG:CBD 1:2 Advanced Formula oral solution
is a high-CBG formulation, manufactured to stringent pharma-quality
standards that brings customers and patients the highest quality
and purity available in the market today. This full-spectrum
formulated oil has a subtle cannabis flavour.
Northbound CBG:CBD The White and Appalachia vape
cartridge is formulated with a terpene blend dominated by citrus
zest and berry aromatic with mild herbal notes to provide balance.
Vaping enables users to experience CBG with a faster onset that is
easier to titrate.
MediPharm is proud to lead the industry in CBG-dominant options
for patients and consumers. CBG is one of the rarer cannabinoids,
and has demonstrated some potential as an antibiotic. An
interdisciplinary team of McMaster researchers, which included
MediPharm's Director of Research and Development, Dr. Tait Gale,
found that CBG was not only antibacterial, but also effective in
mice against a resilient family of bacteria known as
methicillin-resistant Staphylococcus aureus ("MRSA"). Discovering
that CBG has antibacterial properties was significant given that
the MRSA bacterial strain is a leading cause of infections
worldwide and has become increasingly resistant to antibiotics
currently on the market.[1]
MediPharm is also launching a water soluble CBN:THC liquid
solution, Northbound Night Cap. Northbound Night Cap utilizes
proprietary water-soluble emulsification technology developed
in-house by the MediPharm's Research and Development team. This
formulation allows patients and consumers to add CBN to their
favourite food or beverage without overpowering taste and liquid
separation. Using an in-house emulsification method mitigated the
Company's need to purchase or license formulations like many other
cannabis industry beverage brands.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development
and manufacture of purified, pharmaceutical-quality cannabis
concentrates, active pharmaceutical ingredients (API) and advanced
derivative products utilizing a Good Manufacturing Practices
certified facility with ISO standard-built clean rooms. MediPharm
Labs has invested in an expert, research driven team,
state-of-the-art technology, downstream purification methodologies
and purpose-built facilities with five primary extraction lines for
delivery of pure, trusted and precision-dosed cannabis products for
its customers. Through its wholesale and white label platforms,
MediPharm Labs formulates, develops (including through sensory
testing), processes, packages and distributes cannabis extracts and
advanced cannabinoid-based products to domestic and international
markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug
Establishment License from Health Canada, becoming the only company
in North America to hold a
domestic Good Manufacturing License for the extraction of natural
cannabinoids.
Website: www.medipharmlabs.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
statements") within the meaning of the applicable Canadian
securities legislation. All statements, other than statements of
historical fact, are forward-looking statements and are based on
expectations, estimates and projections as at the date of this news
release. Any statement that involves discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives,
assumptions, future events or performance (often but not always
using phrases such as "expects", or "does not expect", "is
expected", "anticipates" or "does not anticipate", "plans",
"budget", "scheduled", "forecasts", "estimates", "believes" or
"intends" or variations of such words and phrases or stating that
certain actions, events or results "may" or "could", "would",
"might" or "will" be taken to occur or be achieved) are not
statements of historical fact and may be forward-looking
statements. In this news release, forward-looking statements relate
to, among other things, statements regarding: leading the industry
in CBN products; distributing the products to the Company's other
seven provincial distributors in the coming months; bringing
differentiated wellness-focused products to market; growing shelf
presence as the year progresses; introduce new products into
international markets; leveraging the Company's unique GMP Drug
Establishment and Natural Health Product manufacturing licenses,
and existing global distribution partnerships; and leading the
industry in CBG-dominant options for patients and consumers.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm Labs to obtain
adequate financing; the delay or failure to receive regulatory
approvals; and other factors discussed in MediPharm Labs' filings,
available on the SEDAR website at www.sedar.com. There can be no
assurance that such statements will prove to be accurate, as actual
results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on the forward-looking statements and
information contained in this news release. Except as required by
law, MediPharm Labs assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change.
__________________________________
|
1 ACS
Infect. Dis. 2020, 6, 3, 338–346 - Publication Date: February 4,
2020, https://doi.org/10.1021/acsinfecdis.9b00419
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medipharm-labs-continues-to-lead-with-innovation--launches-cbg-and-water-soluble-products-301517368.html
SOURCE MediPharm Labs Corp.